Expansion of Autoreactive Unresponsive CD21-/low B Cells in Sjögren's Syndrome-associated Lymphoproliferation
Overview
Authors
Affiliations
Objective: Primary Sjögren's syndrome (SS) is an autoimmune disease associated with a high risk of developing non-Hodgkin's lymphoma. This study was undertaken to determine the nature of B cells driving lymphoproliferation in primary SS.
Methods: B cell subsets and function were analyzed in peripheral blood from 66 adult patients with primary SS (including 14 patients with B cell lymphoproliferative disease [LPD]) and 30 healthy donors, using flow cytometry, calcium mobilization, and gene array analysis. The reactivity of recombinant antibodies isolated from single B cells from patients with primary SS and LPD was tested using an enzyme-linked immunosorbent assay.
Results: We observed an expansion of an unusual CD21-/low B cell population that correlated with lymphoproliferation in patients with primary SS. A majority of CD21-/low B cells from patients with primary SS expressed autoreactive antibodies, which recognized nuclear and cytoplasmic structures. These B cells belonged to the memory compartment, since their Ig genes were mutated. They were unable to induce calcium flux, become activated, or proliferate in response to B cell receptor and/or CD40 triggering, suggesting that these autoreactive B cells may be anergic. However, CD21-/low B cells from patients with primary SS remained responsive to Toll-like receptor (TLR) stimulation. Molecules specifically expressed in CD21-/low B cells that are likely to induce their unresponsive stage were detected in gene array analyses.
Conclusion: Patients with primary SS who display high frequencies of autoreactive and unresponsive CD21-/low B cells are susceptible to developing lymphoproliferation. These cells remain in peripheral blood controlled by functional anergy instead of being eliminated, and chronic antigenic stimulation through TLR stimulation may create a favorable environment for breaking tolerance and activating these cells.
CD21 B cells reveal a unique glycosylation pattern with hypersialylation and hyperfucosylation.
Felixberger P, Andrieux G, Maul-Pavicic A, Goldacker S, Harder I, Gutenberger S Front Immunol. 2025; 16:1512279.
PMID: 40013136 PMC: 11861550. DOI: 10.3389/fimmu.2025.1512279.
Wilbrink R, Neys S, Hendriks R, Spoorenberg A, Kroese F, Corneth O J Transl Autoimmun. 2025; 10:100270.
PMID: 39974741 PMC: 11835616. DOI: 10.1016/j.jtauto.2025.100270.
Sex-specific differences in primary Sjögren's disease.
Punnanitinont A, Kramer J Front Dent Med. 2025; 4:1168645.
PMID: 39916928 PMC: 11797869. DOI: 10.3389/fdmed.2023.1168645.
Know Your ABCs: Discovery, Differentiation, and Targeting of T-Bet+ B Cells.
Winslow G, Levack R Immunol Rev. 2025; 330(1):e13440.
PMID: 39844597 PMC: 11754996. DOI: 10.1111/imr.13440.
Kuijper L, Kreher C, Elias G, Claireaux M, Kerster G, Bos A Front Immunol. 2025; 15:1505719.
PMID: 39742271 PMC: 11686410. DOI: 10.3389/fimmu.2024.1505719.